Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

BACKGROUND: Although TP53 co-mutation with KRAS/ATM/EGFR/STK11 have been proved to have predictive value for response to immune checkpoint inhibitors (ICIs), not all TP53 mutations are equal in this context. As the main part of TP53 mutant types, Missense and Nonsense alternations in TP53 as indepen...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:EBioMedicine
Asıl Yazarlar: Sun, Hao, Liu, Si-Yang, Zhou, Jia-Ying, Xu, Jin-Tian, Zhang, Huang-Kai, Yan, Hong-Hong, Huan, Jiao-Jiao, Dai, Ping-Ping, Xu, Chong-Rui, Su, Jian, Guan, Yan-Fang, Yi, Xin, Yu, Rong-Shan, Zhong, Wen-Zhao, Wu, Yi-Long
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2020
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7494676/
https://ncbi.nlm.nih.gov/pubmed/32927274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.102990
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller